Sep. 12 at 7:19 PM
$CYBN Cybin’s Promising Clinical Advancements and Strategic Positioning Justify Buy Rating
TODAY, Sept 12, 2025, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Cybin, with a price target of
$150.00.
Patrick Trucchio has given his Buy rating due to a combination of factors that highlight Cybin’s promising advancements in their clinical programs.
The company is making steady progress with its late-stage programs, particularly with CYB004 and CYB003. CYB004 has completed Phase 2a enrollment and is expected to release top-line data in the first quarter of 2026, which could significantly influence investor perception of their DMT programs.
Additionally, CYB003 is advancing through the Phase 3 PARADIGM program for major depressive disorder under Breakthrough Therapy Designation, which allows for close FDA engagement
https://www.tipranks.com/news/ratings/cybins-promising-clinical-advancements-and-strategic-positioning-justify-buy-rating-ratings
